Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcadia Biosciences, Inc.RKDA · Entity 8593 | Chief Marketing Officer | April 04, 2023 | April 28, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcadia Biosciences, Inc.
Report date April 04, 2023 · Filed April 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.55 · Expires 2033-04-04 | Direct | 5,300 |
Reported balance
After 2023-04-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-04-04 · Grant · Acquired 1,500 · Balance 5,300 F1: The options were granted on 4/4/2023 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on 4/4/2023 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 04, 2023 Filed Apr 28, 2023 17:30 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $7.55 | $0.00 |
DisclosureSEC source: 0001209191-23-026082 · doc4.xml · derivative · entry 1 PITLIK LAURA · CIK 0001872366 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 1,500 shares Expires 2033-04-04 F1 · derivative.exercise_date: The options were granted on 4/4/2023 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 21:00 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 23,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001209191-22-046793 · doc4.xml · derivative · entry 1 PITLIK LAURA · CIK 0001872366 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,000 Underlying: Common Stock · 23,000 shares Expires 2032-08-16 F1 · derivative.exercise_date: The option vests in two equal installments occurring on the first, and second anniversary of the date of grant. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 16:01 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 23,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-22-024268 · doc4.xml · derivative · entry 2 PITLIK LAURA · CIK 0001872366 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,000 Underlying: Common Stock · 23,000 shares Expires 2032-04-11 F2 · derivative.exercise_date: The Option vests in two equal installments occurring on the first, and second anniversary of the date of grant, subject to the Participant's continued service. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 16:01 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 31,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-22-024268 · doc4.xml · derivative · entry 1 PITLIK LAURA · CIK 0001872366 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,000 Underlying: Common Stock · 31,000 shares Expires 2032-04-11 F1 · derivative.exercise_date: 25% of the total number of shares subject to the Option will vest on the first anniversary of the date of the award; the remaining 75% will vest in 36 equal installments, subject to the Participant's continued service. Read SEC document |
| July 12, 2021 Filed Jul 13, 2021 18:33 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001209191-21-046592 · doc4.xml · derivative · entry 1 PITLIK LAURA · CIK 0001872366 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-07-12 F1 · derivative.exercise_date: 25% of the total number of shares subject to the Option will vest on the first anniversary of the date of the award; the remaining 75% will vest in 36 equal installments, subject to the Participant's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.